Clinical Trial Update: Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating nivolumab and ipilimumab in patients with T1aN0M0 renal cell carcinoma ineligible for surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Kidney Cancer Research Bureau | Conditions: Renal Cell Carcinoma | Phase 2 | Status: UNKNOWN